ArticleJournal of neurochemistry2026
Unveiling the Molecular Mechanism of Intestinal Metabolite para-Cresol in Modulating Neuroinflammation and Synaptic Dysfunction: Implications for Autism Spectrum Disorder.
Article in Journal of neurochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preface to the Special Issue: "Microbiota and Gut-Brain Axis".Journal of neurochemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Autism spectrum disorder (ASD) is a diverse group of neurodevelopmental disorders that share similar behavioral patterns. Many individuals with ASD also exhibit gastrointestinal disturbances, likely linked to alterations in the composition and activity of intestinal bacteria, resulting in the overproduction and release of toxic metabolites into the systemic circulation. These toxins may reach the central nervous system (CNS) and activate microglia, which release inflammatory cytokines, ultimately impairing neuronal function. This microbiota-gut-brain axis has been suggested to play a crucial role in the pathogenesis of ASD. Para-cresol (p-Cresol) is one of these intestinal metabolites and could potentially contribute to ASD, as its urinary levels are elevated in autistic children under the age of 8 and correlate with symptom severity. Here, we aim to investigate the effect of p-Cresol on various brain-cell types to speculate on their specific contributions to ASD-related synaptic dysfunctions. Immunocytochemistry assays revealed a significant decrease in excitatory (vesicular glutamate transporter VGLUT, postsynaptic density protein 95 PSD95) and inhibitory (vesicular GABA transporter VGAT) synaptic markers in p-Cresol-treated neurons during synaptogenesis. These effects were exacerbated in SH3 and multiple ankyrin repeat domains 3 (Shank3) knockdown neurons, which exhibit increased susceptibility of their synapses. p-Cresol also induced a dose-dependent inflammatory response in both astrocytes and microglia, characterized by the overexpression and release of inflammatory cytokines and chemokines such as interleukin 6 (IL6), interleukin 1β (IL1β), and C-C- motif chemokine ligand 3 (CCL3). Our results suggest that p-Cresol exerts cell-specific effects on astrocytes and microglia, and the release of inflammatory cytokines and chemokines in response to p-Cresol treatment may contribute to synaptic dysfunction, in addition to its direct effect on neurons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.